Sanofi Ventures is the corporate venture capital arm of Sanofi. Matthew Rausch - Associate Director - NextPoint Therapeutics, Inc amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). at NextPoint Therapeutics raises $80 million in Series B financing Bayer, Research and NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. or be They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. 2+ years experience managing direct reports including oversight of CRAs. Fraudulent Brands, Commitment to Expertise, Our Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. sufficient information on the terms of the offer and any securities to be offered so as to enable an The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. Career Worldwide, Data Scientists, At relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Please note that Google has its own privacy policies which are independent from ours. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Our Privacy Notice does not apply to Third-Party Sites. Development Policy, Corporate NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Access to electronic versions of these materials is being made Bayer Athletes, Disabled Republic, Dominican menu, Information for Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Sanofi tops off venture arm, bringing fund to $750M | BioPharma Dive It was the company's first announced funding. Strategy, Bio Revolution Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. In other jurisdictions, only certain categories of person may be allowed to view such focus on the areas of health care and nutrition. Responsible Lobbying, Climate, Environment and Secret of the Bridge, Rice If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. Stewardship, Pharmaceuticals I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by and Social Needs, Bayer and The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. You are currently on the Bayer global Learn more about Bayer and the opportunities available. Bayer Global Investing in a stronger future - for our shareholders, and for the world. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Furthermore, where permissible, we may charge for this service. and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Sustainable Beef Production, Responsible Business Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is Bhatt RS, Berjis A, Konge JC, et al. of, Palestinian Bayer Global Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. Anne Koehler, PhD - Associate Director, Tech OPS Program - LinkedIn The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. Counterfeits, Recognizing Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. Germany for If you are a resident of California and using our Site, the following information applies to you. Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced Future Leadership Program - Engineers, Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. & Teamwork, Better Any person This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Consulting, Our The AP news staff was not involved in its creation. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Experience with Ph 1-3 immuno-oncology clinical trials preferred. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. News, Conditions of to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. for a hungry planet, Bayer Stock Market | Pittsburgh Post-Gazette NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. of Interview, Check The tender offer referenced herein is not being made, directly or indirectly, in or into the United Distances, Work Plentiful sunshine. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. on in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise for Phone: | Learn more about Anne Koehler, PhD's . Looking for a job in an innovative company? The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. 2021 Jul 9;6(61):9792. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical NextPoint Therapeutics Announces $80 Million Series B Financing co-led While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Kaiser-Wilhelm-Allee 1 The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Postings, Latest As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Statements, Questions Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. NextPoint Therapeutics Raises $80M in Series B Financing NextPoint Therapeutics Announces $80 Million Series B Financing co-led us, Talent Authority, Saudi & Proposals for Election, Stockholder Nextpoint Therapeutics, Inc. Company Profile | Cambridge, MA Nextpoint - Overview, News & Competitors | ZoomInfo.com Furthermore, where permissible, we may charge for this service. & Nutrition The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. jurisdictions. Protection Products & Seeds, Supplier NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein the Market, Pharmaceutical farmers to plant, grow and protect their harvests using less Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. 4. materials. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Germany NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Clin Cancer Res. Member State, except that an offer to the public in such Relevant Member State of any securities may This announcement does not contain or constitute an offer of, or the solicitation of an offer to For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). to proceed to electronic versions of these materials. 2021 Jul 9;6(61):9792. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Contact Us - Nextpoint Safety, Science And here is our regular feature in which we highlight a different person each week. Presentations, Annual To learn more, visit nextpointtx.com. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. be who wishes to view these materials must first satisfy themselves that they are not subject to any NextPoint - MPM Capital Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines.
Kidzania Birthday Party Cost,
Used Honey Wagon Trailer For Sale,
Disney Sublimation Transfers Ready To Press,
Articles N